Abstract: A method of treating postprandial inflammation, or inhibiting an inflammatory response in a subject, may include administering to a subject an edible composition comprising an ACSL1 inhibitor. The ACSL1 inhibitor may be administered before or during consumption of a food high in fat, particularly a food high in saturated fat. The ACSL1 inhibitor may prevent a pro-inflammatory response, weight gain, or the development or progression of a disease associated with the consumption of high fat foods, such as dyslipidemia, obesity, diabetes, arthritis, or hepatic steatosis.

Abstract: Methods of inhibiting MMP-9 are provided. The methods of inhibiting MMP-9 include methods of inhibiting IL-6/TNF-? crosstalk mediated expression and/or secretion of MMP-9. The inhibition of the IL-6/TNF-? crosstalk pathway may be accomplished using an IL-6 signaling inhibitor, such as AG490 or SC-144. The methods may also include the treatment of dieses through the inhibition of IL-6/TNF-? crosstalk mediated production of MMP-9. In an embodiment the methods may include preventing the progression of cancer or cardiovascular disease through the inhibition of the IL-6/TNF-? crosstalk pathway.

Abstract: A method of treating postprandial inflammation may include administering to a subject an edible composition comprising the ACSL1 inhibitor within hours of the subject consuming a food. The edible composition may be administered by consumption by the subject at the same time as the subject consumes the food. The food may be high in saturated fatty acids.